On Tuesday, Vaxcyte got a positive adjustment to its Relative Strength (RS) Rating, from 68 to 72.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks typically have an 80 or better RS Rating as they begin their largest runs. See if Vaxcyte can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vaxcyte is now considered extended and out of buy range after clearing a 76.00 buy point in a second-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Vaxcyte posted 0% EPS growth in the latest quarterly report. Sales increased 0%.
Vaxcyte earns the No. 282 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
